Newborn Screening for Severe Combined Immunodeficiency Improves Survival
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 28, 2023 -- Newborn screening for severe combined immunodeficiency (SCID) facilitating early identification results in improved survival, according to a study published online June 20 in The Lancet.
Monica S. Thakar, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues analyzed transplantation-related data from children with SCID treated at 34 sites for 1982 to 1989, 1990 to 1999, 2000 to 2009, and 2010 to 2018 to examine factors affecting survival, focusing on SCID screening that was initiated in 2008 and expanded during 2010 to 2018. Data were included for 902 children with confirmed SCID.
The researchers found that the five-year overall survival remained stable for 28 years at 72 to 73 percent until 2010 to 2018, when it increased to 87 percent. Five-year overall survival was 92.5 percent for children identified as having SCID by newborn screening since 2010, which was better than that of children identified by clinical illness or family history during the same period (79.9 and 85.4 percent, respectively). During all time intervals, the factors of active infection, age 3.5 months or older at hematopoietic cell transplantation (HCT), Black or African-American race (hazard ratios, 2.41, 2.12, and 2.33, respectively), and certain SCID genotypes were associated with lower overall survival. HCT after 2010 no longer conveyed a survival advantage over earlier time intervals studied after adjustment for multiple variables.
"Our findings summarize the evolution of almost four decades of transplant practices and provide direct evidence that newborn screening for SCID has been the primary driver of improved survival in newborn babies in the USA and Canada since 2010," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Alternative Pembrolizumab Administration Yields Environmental Advantages
THURSDAY, June 13, 2024 -- Alternative pembrolizumab administration strategies may have environmental advantages, such as less carbon dioxide emission, according to a study...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 -- There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory...
American College of Obstetricians and Gynecologists, May 17-19
The annual meeting of the American College of Obstetricians and Gynecologists was held from May 17 to 19 in San Francisco and was attended by more than 4,000 clinicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.